1988Journal of ExtraCorporeal TechnologyOpen access

Extended Extracorporeal Support Utilizing Minimal Heparin and Iloprost (ZK36374)

William B. Pelley, Donald D. Taylor, Charles F. Butler

Open full text 0 citations

Abstract

Iloprost (ZK36374), a prostacyclin analogue, has been shown to preserve platelet ultrastructure and reactivity. In an effort to reduce adverse platelet alterations, iloprost was utilized in three patients undergoing extended extra-corporeal support (EECS). EECS times ranged from 21 to 46 hours. One patient was able to be weaned from EECS. iloprost allowed EECS in one patient who was heparin sensitive. All three patients demonstrated no platelet aggregation when challenged by ADP during iloprost infusion. Platelet reactivity returned to normal in the patient who was successfully weaned from EECS after iloprost was discontinued. Iloprost allowed EECS to be performed with minimal heparinization. We conclude that minimal heparinization and iloprost may be a valuable addition for those patients requiring extended extra-corporeal support.

Open-access reader

About this research paper

What this paper is about

Iloprost (ZK36374), a prostacyclin analogue, has been shown to preserve platelet ultrastructure and reactivity. In an effort to reduce adverse platelet alterations, iloprost was utilized in three patients undergoing extended extra-corporeal support (EECS). EECS times ranged from 21 to 46 hours. One patient was able to be weaned from EECS. iloprost allowed EECS in one patient who was heparin sensitive. All three patients demonstrated no platelet aggregation when challenged by ADP during iloprost infusion. Platelet reactivity returned to normal in the patient who was successfully weaned from EECS after iloprost was discontinued. Iloprost allowed EECS to be performed with minimal heparinization. We conclude that minimal heparinization and iloprost may be a valuable addition for those patients requiring extended extra-corporeal support.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Iloprost (ZK36374), a prostacyclin analogue, has been shown to preserve platelet ultrastructure and reactivity. In an effort to reduce adverse platelet alterations, iloprost was utilized in three patients undergoing extended extra-corporeal support (EECS). EECS times ranged from 21 to 46 hours. One patient was able to be weaned from EECS. iloprost allowed EECS in one patient who was heparin sensitive. All three patients demonstrated no platelet aggregation when challenged by ADP during iloprost infusion. Platelet reactivity returned to normal in the patient who was successfully weaned from EECS after iloprost was discontinued. Iloprost allowed EECS to be performed with minimal heparinization. We conclude that minimal heparinization and iloprost may be a valuable addition for those patients requiring extended extra-corporeal support.

Key concepts: Iloprost, Prostacyclin, Medicine, Platelet, Extracorporeal, Heparin, Anesthesia, Heparin-induced thrombocytopenia

Related papers

Back to paper searchBrowse research topicsOriginal source
Extended Extracorporeal Support Utilizing Minimal Heparin and Iloprost (ZK36374) — Research Paper | ScholarLens